약물 방출 풍선 카테터 시장 : 시장 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of drug-eluting balloon catheters Market

The global drug-eluting balloon catheters market was valued at USD 778.05 million in 2025 and is projected to reach USD 846.34 million in 2026, eventually growing to USD 2,053.26 million by 2034, representing a robust CAGR of 11.72% during 2026-2034. The market's growth is primarily driven by the rising prevalence of cardiovascular diseases, increasing adoption of minimally invasive procedures, and the advantages of drug-eluting balloon catheters (DEBCs) over traditional drug-eluting stents (DES).

Drug-eluting balloon catheters, also known as drug-coated balloon catheters, are advanced devices that deliver anti-proliferative drugs directly into the vessel wall via inflated balloons. This targeted drug delivery restores luminal vascularity, treats atherosclerosis and in-stent restenosis, and reduces the risk of late thrombosis without leaving a permanent implant. The technology supports rapid healing of the vessel wall and prevents smooth muscle cell proliferation, positioning it as a safer alternative to DES.

Market Segmentation and Key Drivers

By drug type, the paclitaxel segment dominated the market in 2026, accounting for 93.72% of the market with a size of USD 793.16 million. Paclitaxel-eluting balloon catheters have a well-established presence, and the launch of new products continues to drive segment growth. The sirolimus segment is expected to witness a significant CAGR due to its stronger anti-proliferative effect on atherosclerosis-related hypoxic cells, making it suitable for treating vascular restenosis.

In terms of indication, the peripheral intervention segment accounted for 76.00% of the market in 2026, valued at USD 643.24 million, driven by the growing prevalence of peripheral artery disease (PAD) and targeted product launches. The coronary intervention segment is expected to grow at the fastest CAGR, with clinical trials and new product approvals, such as Boston Scientific's Agent paclitaxel-coated PTCA balloon catheter trial in Japan, contributing to growth.

By end-user, hospitals and ambulatory surgical centers (ASCs) held the largest share in 2026, contributing 66.32% of the market (USD 561.3 million), due to higher hospital expenditure and patient preference for comprehensive diagnosis and treatment. Specialty clinics and catheterization laboratories are also expected to expand significantly as more catheterization facilities increase accessibility to coronary and peripheral vascular procedures.

Regional Insights

North America dominated the global market in 2025 with a 48.84% share, totaling USD 380.04 million, due to high PAD and coronary artery disease (CAD) prevalence, technological advancements, and presence of key players like Medtronic and BD. The U.S. market is projected to reach USD 381.95 million by 2026, with 8-12 million people affected by PAD.

Europe also holds a strong position, with Germany, France, and the U.K. contributing significantly due to advanced healthcare infrastructure and rising vascular disease cases. The UK market is projected to reach USD 36.31 million by 2026, while Germany is expected to reach USD 58.78 million.

The Asia Pacific market is projected to grow at the fastest CAGR, driven by increasing patient preference for minimally invasive procedures and rising PAD prevalence. Japan, China, and India are expected to reach USD 41.38 million, USD 44.49 million, and USD 19.37 million, respectively, by 2026. Latin American countries like Brazil and Mexico are witnessing rising PAD cases and improved access to advanced interventions. Gradual adoption is observed in the Middle East & Africa, though regulatory hurdles persist.

Industry Players and Developments

Prominent market players include Medtronic, BD, B. Braun SE, Boston Scientific Corporation, Koninklijke Philips N.V., MicroPort Medical (Group) Co., Ltd., Meril Life Sciences Pvt. Ltd., BIOTRONIK, and Cordis. Companies focus on R&D and new product launches to expand market presence. Notable developments include:

• August 2022: BD launched a first-in-human trial of a peripheral sirolimus drug-coated balloon to study PAD treatment efficacy.
• January 2021: MicroPort received EU CE mark for Reewarm PTX DCB PTA catheter for femoral popliteal artery interventions.
• November 2020: Boston Scientific obtained FDA approval for Ranger DCB to treat PAD, SFA, and PPA.
• October 2019: Philips received FDA approval for Stellarex low-dose DCBs.
• June 2017: Philips acquired Spectranetics to enhance its DCB portfolio.

Market Restraints

Despite growth, DEBC adoption faces challenges. Studies highlight high mortality risks with paclitaxel-coated balloons in femoropopliteal arteries, potentially limiting adoption. Medtronic has issued warnings regarding late mortality risks with its IN.PACT AV DCB. Additionally, stringent regulations-particularly the lack of FDA-approved coronary DEBCs in the U.S.-may hinder market expansion.

COVID-19 Impact

The pandemic temporarily reduced demand, with global revenues declining by -13.7% in 2020 due to fewer angioplasty procedures. Boston Scientific experienced an 18.4% revenue drop in interventional cardiology in 2020. Recovery began in 2021 with eased restrictions and resumed procedures, increasing DEBC demand globally.

Conclusion

The drug-eluting balloon catheters market is poised for strong growth from USD 778.05 million in 2025 to USD 2,053.26 million by 2034, driven by rising heart disease prevalence, technological advancements, minimally invasive interventions, and product innovation. While regulatory challenges and safety concerns exist, the market's expansion, particularly in North America and Asia Pacific, signals a promising future for DEBC adoption worldwide.

Segmentation By Drug

• Paclitaxel
• Sirolimus
• Others

By Indication

• Coronary Intervention
• Peripheral Intervention

By End-user

• Hospitals & ASCs
• Specialty Clinics and Catheterization Laboratories

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
• Rest of the World

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Peripheral Artery Disease (PAD), in 2025 - By Region
• 4.2. Pipeline Analysis
• 4.3. New Product Launches
• 4.4. Key Industry Developments
• 4.5. Impact of COVID-19 on the Market

5. Global Drug-eluting Balloon Catheters Market Analysis, Insights and Forecast, 2025-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug
  • 5.1.1. Paclitaxel
  • 5.1.2. Sirolimus
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Indication
  • 5.2.1. Coronary intervention
  • 5.2.2. Peripheral intervention
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Hospitals & ASCs
  • 5.3.2. Specialty Clinics and Catheterization Laboratories
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Rest of the World

6. North America Drug-eluting Balloon Catheters Market Analysis, Insights and Forecast, 2025-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug
  • 6.1.1. Paclitaxel
  • 6.1.2. Sirolimus
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Indication
  • 6.2.1. Coronary intervention
  • 6.2.2. Peripheral intervention
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Hospitals & ASCs
  • 6.3.2. Specialty Clinics and Catheterization Laboratories
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Drug-eluting Balloon Catheters Market Analysis, Insights and Forecast, 2025-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug
  • 7.1.1. Paclitaxel
  • 7.1.2. Sirolimus
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Indication
  • 7.2.1. Coronary intervention
  • 7.2.2. Peripheral intervention
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Hospitals & ASCs
  • 7.3.2. Specialty Clinics and Catheterization Laboratories
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Drug-eluting Balloon Catheters Market Analysis, Insights and Forecast, 2025-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug
  • 8.1.1. Paclitaxel
  • 8.1.2. Sirolimus
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Indication
  • 8.2.1. Coronary intervention
  • 8.2.2. Peripheral intervention
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Hospitals & ASCs
  • 8.3.2. Specialty Clinics and Catheterization Laboratories
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Rest of the World Drug-eluting Balloon Catheters Market Analysis, Insights and Forecast, 2025-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug
  • 9.1.1. Paclitaxel
  • 9.1.2. Sirolimus
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Indication
  • 9.2.1. Coronary intervention
  • 9.2.2. Peripheral intervention
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Hospitals & ASCs
  • 9.3.2. Specialty Clinics and Catheterization Laboratories

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles (Overview, Product, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
  • 10.2.1. Medtronic
    • 10.2.1.1. Overview,
    • 10.2.1.2. Product,
    • 10.2.1.3. SWOT Analysis,
    • 10.2.1.4. Recent Developments,
    • 10.2.1.5. Strategies,
    • 10.2.1.6. financials (Based on Availability)
  • 10.2.2. Koninklijke Philips N.V.
    • 10.2.2.1. Overview,
    • 10.2.2.2. Product,
    • 10.2.2.3. SWOT Analysis,
    • 10.2.2.4. Recent Developments,
    • 10.2.2.5. Strategies,
    • 10.2.2.6. financials (Based on Availability)
  • 10.2.3. Boston Scientific Corporation
    • 10.2.3.1. Overview,
    • 10.2.3.2. Product,
    • 10.2.3.3. SWOT Analysis,
    • 10.2.3.4. Recent Developments,
    • 10.2.3.5. Strategies,
    • 10.2.3.6. financials (Based on Availability)
  • 10.2.4. BD
    • 10.2.4.1. Overview,
    • 10.2.4.2. Product,
    • 10.2.4.3. SWOT Analysis,
    • 10.2.4.4. Recent Developments,
    • 10.2.4.5. Strategies,
    • 10.2.4.6. financials (Based on Availability)
  • 10.2.5. B. Braun SE
    • 10.2.5.1. Overview,
    • 10.2.5.2. Product,
    • 10.2.5.3. SWOT Analysis,
    • 10.2.5.4. Recent Developments,
    • 10.2.5.5. Strategies,
    • 10.2.5.6. financials (Based on Availability)
  • 10.2.6. Meril Life Sciences Pvt. Ltd.
    • 10.2.6.1. Overview,
    • 10.2.6.2. Product,
    • 10.2.6.3. SWOT Analysis,
    • 10.2.6.4. Recent Developments,
    • 10.2.6.5. Strategies,
    • 10.2.6.6. financials (Based on Availability)
  • 10.2.7. BIOTRONIK
    • 10.2.7.1. Overview,
    • 10.2.7.2. Product,
    • 10.2.7.3. SWOT Analysis,
    • 10.2.7.4. Recent Developments,
    • 10.2.7.5. Strategies,
    • 10.2.7.6. financials (Based on Availability)
  • 10.2.8. Cordis
    • 10.2.8.1. Overview,
    • 10.2.8.2. Product,
    • 10.2.8.3. SWOT Analysis,
    • 10.2.8.4. Recent Developments,
    • 10.2.8.5. Strategies,
    • 10.2.8.6. financials (Based on Availability)
  • 10.2.9. MicroPort Medical (Group) Co., Ltd.
    • 10.2.9.1. Overview,
    • 10.2.9.2. Product,
    • 10.2.9.3. SWOT Analysis,
    • 10.2.9.4. Recent Developments,
    • 10.2.9.5. Strategies,
    • 10.2.9.6. financials (Based on Availability)